Pulmonary Hypertension
Conditions
Interventions
Trade Name: Sustanon 100
Product Name: Sustanon 100
Pharmaceutical Form: Solution for injection
INN or Proposed INN: Testosterone Propionate
Sponsors
Sheffield teaching Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Male aged over 18 on regular medication unlikely to change Clinical pulmonary hypertension, diagnosed 3 months and clinically stable Pulmonary hypertension diagnosed on echocardiography or by right heart catheter: peak systolic pulmonary artery pressure>50mmHg, mean 30mmHg. NYHA class II or III Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Unable to perform shuttle walk test or comply with medication Malignancy e.g. breast and prostate. Left heart failure – Ejection fraction <40% on echocardiography Nephrotic syndrome History of primary liver tumours Hypercalcaemia and hypercalciuria Hormone manipulating therapy PSA above the normal range NYHA class IV Current participation in other research projects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the effects of testosterone supplementation as add on therapy in men with pulmonary hypertension as defined by an increase in shuttle walk distance;Secondary Objective: To evaluate the effects of testosterone supplementation as add on therapy on cardiorespiratory, endoparacrine and quality of life measures in men with pulmonary hypertension;Primary end point(s): Change in functional capacity defined as increase in distance walked on shuttle walk testing | — |
Countries
United Kingdom
Outcome results
None listed